Skip to main content

Advertisement

Table 1 Characteristics of the 511 diffuse large B-cell lymphoma (DLBCL) patients in the entire cohort and the central nervous system (CNS) relapse cohort (CHOP vs. R-CHOP)

From: New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study

Clinical factor Entire cohort [cases (%)] CNS relapse cohort [cases (%)]
CHOP R-CHOP P CHOP R-CHOP P
Total 135 376   11 14  
Age    0.563    1.000
 ≤60 years 98 (72.6) 263 (69.9)   8 (72.7) 10 (71.4)  
 >60 years 37 (27.4) 113 (30.1)   3 (27.3) 4 (28.6)  
Gender    0.694    0.115
 Male 76 (56.3) 219 (58.2)   5 (45.5) 11 (78.6)  
 Female 59 (43.7) 157 (41.8)   6 (54.5) 3 (21.4)  
Stage    0.892    0.434
 I or II 77 (57.0) 217 (57.7)   5 (45.5) 4 (28.6)  
 III or IV 58 (43.0) 159 (42.3)   6 (54.5) 10 (71.4)  
B symptoms    0.663    1.000
 No 95 (70.4) 272 (72.3)   7 (63.6) 8 (57.1)  
 Yes 40 (29.6) 104 (27.7)   4 (36.4) 6 (42.9)  
Bulky diseasea,b    0.238    0.500
 No 91 (67.4) 252 (67.0)   6 (54.5) 8 (57.1)  
 Yes 10 (7.4) 17 (4.5)   0 (0) 2 (14.3)  
Involved extranodal sitesc    0.617    0.414
 ≤1 112 (83.0) 303 (80.6)   8 (72.7) 7 (50)  
 >1 23 (17.0) 71 (18.9)   3 (27.3) 7 (50)  
Sinus involvement    0.971    0.604
 No 119 (88.1) 331 (88.0)   10 (90.9) 11 (78.6)  
 Yes 16 (11.9) 45 (12.0)   1 (9.1) 3 (21.4)  
Bone involvement    0.947    0.407
 No 120 (88.9) 335 (89.1)   9 (81.8) 9 (64.3)  
 Yes 15 (11.1) 41 (10.9)   2 (18.2) 5 (35.7)  
Bone marrow involvement    0.177    0.230
 No 133 (98.5) 360 (95.7)   11 (100) 11 (78.6)  
 Yes 2 (1.5) 16 (4.3)   0 (0) 3 (21.4)  
Liver involvement    0.792    0.487
 No 131 (97.0) 361 (96.0)   11 (100) 12 (85.7)  
 Yes 4 (3.0) 15 (4.0)   0 (0) 2 (14.3)  
Testicular involvement    0.526    1.000
 No 131 (97.0) 368 (97.9)   11 (100) 13 (92.9)  
 Yes 4 (3.0) 8 (2.1)   0 (0) 1 (7.1)  
Renal involvement    0.782    0.661
 No 130 (96.3) 360 (95.7)   9 (81.8) 10 (71.4)  
 Yes 5 (3.7) 16 (4.3)   2 (18.2) 4 (28.6)  
Breast involvement    0.318   
 No 130 (96.3) 368 (97.9)   11 (100) 14 (100)  
 Yes 5 (3.7) 8 (2.1)   0 (0) 0 (0)  
Female genital tract involvement    0.063   
 No 131 (97.0) 373 (99.2)   11 (100) 14 (100)  
 Yes 4 (3.0) 3 (0.8)   0 (0) 0 (0)  
IPI    0.096    0.208
 0–2 113 (83.7) 289 (76.9)   9 (81.8) 7 (50.0)  
 3–5 22 (16.3) 87 (23.1)   2 (18.2) 7 (50.0)  
LDHd    0.768    0.677
 ≤1 ULNe 79 (58.5) 215 (57.2)   3 (27.3) 6 (42.9)  
 >1 ULN 55 (40.7) 159 (42.3)   8 (72.7) 8 (57.1)  
ALB    0.464    0.656
 <35 g/L 114 (84.4) 327 (87.0)   4 (36.4) 3 (21.4)  
 ≥35 g/L 21 (15.6) 49 (13.0)   7 (63.6) 11 (78.6)  
ALPf    0.529    1.000
 ≤110 U/L 119 (88.1) 341 (90.7)   8 (72.7) 10 (71.4)  
 >110 U/L 15 (11.1) 35 (9.3)   3 (27.3) 4 (28.6)  
IT chemotherapy prophylaxisg    0.640    0.661
 No 117 (86.7) 329 (87.5)   9 (81.8) 10 (71.4)  
 Yes 18 (13.3) 44 (11.7)   2 (18.2) 4 (28.6)  
TTCh    0.016    0.003
 ≤108 days 54 (40.0) 207 (55.1)   0 (0) 7 (50.0)  
 >108 days 67 (49.6) 155 (41.2)   10 (90.9) 3 (21.4)  
  1. CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, IPI international prognostic index, LDH lactate dehydrogenase, ULN upper limit of normal, ALB albumin, ALP alkaline phosphatase, IT intrathecal, TTC time to complete remission
  2. aBulky disease: mass ≥7.5 cm
  3. bIn the entire cohort, the data of 34 patients in the CHOP group and seven patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of five patients in the CHOP group and four patients in the R-CHOP group were missing
  4. cIn the entire cohort, the data of two patients in the R-CHOP group were missing
  5. dIn the entire cohort, the data of one patient in the CHOP group and two patients in the R-CHOP group were missing
  6. fIn the entire cohort, the data of one patient in the CHOP group were missing
  7. gIn the entire cohort, the data of three patients in the R-CHOP group were missing
  8. hIn the entire cohort, the data of 14 patients in the CHOP group and 14 patients in the R-CHOP group were missing; in the CNS relapse cohort, the data of one patient in the CHOP group and four patients in the R-CHOP group were missing